Vectors for enhanced expression of VEGF for atrial disease treatment
The invention provides a vector which is capable of the expression of a vascular endothelial growth factor wherein the vector comprises a modified PCMV promoter. The invention further provides use of a vector which is capable of and expressing a vascular endothelial growth factor (VEGF) for the regulation of endothelial function, angiogenesis and arteriogenesis. The invention further comprises use of a vector which is capable of the expression of a vascular endothelial growth factor (VEGF) for the prophylactic treatment of arterial diseases and/or bone marrow diseases and/or neural diseases.
1. A vector comprising a DNA sequence encoding human vascular endothelial growth factor, wherein said nucleic acid sequence comprises nucleotides 682–1258 of SEQ ID NO: 6 operably linked to a modified pCMV promoter of nucleotides 14–619 of SEQ ID NO: 6.
2. An isolated host cell which comprises a vector according to claim 1 .
3. An isolated host cell according to claim 2 , which is a human cell.
4. A composition comprising a vector according to claim 1 .
5. A pharmaceutical composition comprising a vector according to claim 1 and a pharmaceutically acceptable carrier.
6. A method of treatment of arterial diseases, comprising intramuscularly administering a vector according to claim 1 with a carrier to a suitable recipient, wherein production of said VEGF results in an increase in the number of collateral blood vessels in ischemic tissues and/or improved blood flow.
7. A method of treatment of arterial diseases, comprising intramuscularly administering a composition according to claim 4 or 5 to a suitable recipient, wherein production of said VEGF results in an increase in the number of collateral blood vessels in ischemic tissues and/or improved blood flow.